Diethylpropion Hydrochloride

EMA’s safety committee ( PRAC ) has confirmed its recommendation to withdraw the marketing authorisations for amfepramone obesity medicines. This follows a re-examination of its previous recommendation of June 2022, which was requested by the companies that market these medicines. The recommendation follows a review which found that measures to restrict the use of these medicines for safety reasons have not been sufficiently effective. It found that the medicines were being used for longer than the recommended maximum period of 3 months, thereby potentially increasing the risk of serious side effects such as pulmonary arterial hypertension (high blood pressure in the lungs) and dependency. The medicines were also being used in patients with a history of heart disease or psychiatric disorders, increasing their risk of heart and psychiatric problems. In addition, there was evidence of use during pregnancy, which could pose risks to the unborn baby. The review considered all available information relating to these concerns, including data from two studies on the use of amfepramone medicines in Germany and in Denmark. In addition, the PRAC received advice from a group of experts, comprising endocrinologists, cardiologists and a patient representative. The PRAC considered introducing further measures to minimise the risk of side effects but could not identify any that would be sufficiently effective. The PRAC therefore concluded that the benefits of amfepramone medicines do not outweigh their risks and recommended that the medicines be removed from the market in the EU. The PRAC recommendation will now be sent to the CMDh 1 for its consideration. Information for patients EMA is recommending that amfepramone obesity medicines should no longer be available because they are not always used as recommended. Inappropriate use can cause serious side effects, such as increased blood pressure in arteries of the lungs, heart disease, dependency, psychiatric problems and harm to the unborn baby. In addition, the benefits of using these medicines in the treatment of obesity are considered limited. Other obesity treatment options are available. Contact your doctor to discuss which treatment would be suitable for you. If you have other questions or concerns about amfepramone medicines, speak to your doctor or pharmacist. Information for healthcare professionals EMA is recommending the withdrawal of the EU marketing authorisations for amfepramone medicines for the treatment of obesity. A review of available data has found that amfepramone medicines continue to be used outside the current risk minimisation measures included in the product information . Inappropriate use may increase the risk of serious adverse effects, including cardiovascular disease, pulmonary arterial hypertension, dependency and psychiatric disorders, as well as harmful effects if used during pregnancy. A review of available data also indicates that the efficacy of amfepramone in the treatment of obesity is limited. Healthcare professionals should advise patients about other treatment options. A direct healthcare professional communication (DHPC) will be sent in due course to healthcare professionals prescribing or dispensing the medicine and published on a dedicated page on the EMA website. More about the medicine Amfepramone is a sympathomimetic, which means that it acts in the brain and causes effects that are similar to those of adrenaline. Such medicines reduce a feeling of hunger. Amfepramone medicines are currently authorised in Denmark, Germany and Romania as treatment for patients with obesity (body mass index of at least 30kg/m 2 ) in whom other weight-reduction methods have not worked on their own. Amfepramone medicines were authorised to be used for 4 to 6 weeks and no longer than 3 months. Within the EU, amfepramone medicines are available under the following trade names: Amfepramon‑Hormosan 25 mg Weichkapseln, Amfepramon‑Hormosan 60 mg Retardkapseln, Regenon, Tenuate Retard 75 mg retardtablette and Regenon 25 mg capsule moi. More about the procedure The review of amfepramone medicines has been initiated at the request of the Romanian medicines agency (NAMMDR), under Article 31 of Directive 2001/83/EC . The review has been carried out by the Pharmacovigilance Risk Assessment Committee ( PRAC ), the Committee responsible for the evaluation of safety issues for human medicines, which has made a set of recommendations. Following a re-examination requested by the marketing authorisation holders , the PRAC subsequently confirmed its conclusions for amfepramone-containing medicines. Because these medicines are all authorised at national level, the PRAC recommendations will now be sent to the CMDh , which will adopt a position. The CMDh is a body representing EU Member States as well as Iceland, Liechtenstein and Norway. It is responsible for ensuring harmonised safety standards for medicines authorised via national procedures across the EU. This review follows previous reviews on the benefits and risks of appetite-suppressing medicines (including amfepramone) in 1996 and 1999. 1 Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human

EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders EMA’s safety committee ( PRAC ) has recommended measures to minimise the risk of serious side effects associated with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders. These side effects include cardiovascular conditions, blood clots, cancer and serious infections. The Committee recommended that these medicines should be used in the following patients only if no suitable treatment alternatives are available: those aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. The Committee also recommended using JAK inhibitors with caution in patients with risk factors for blood clots in the lungs and in deep veins (venous thromboembolism, VTE) other than those listed above. Further, the doses should be reduced in some patient groups who may be at risk of VTE, cancer or major cardiovascular problems. The recommendations follow a review of available data, including the final results from a clinical trial 1 of the JAK inhibitor Xeljanz (tofacitinib) and preliminary findings from an observational study involving Olumiant (baricitinib), another JAK inhibitor. During the review, the PRAC sought advice from an expert group of rheumatologists, dermatologists, gastroenterologists and patient representatives. The review confirmed Xeljanz increases the risk of major cardiovascular problems, cancer, VTE, serious infections and death due to any cause when compared with TNF-alpha inhibitors. The PRAC has now concluded that these safety findings apply to all approved uses of JAK inhibitors in chronic inflammatory disorders (rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, ulcerative colitis, atopic dermatitis and alopecia areata). The product information for JAK inhibitors used to treat chronic inflammatory disorders will be updated with the new recommendations and warnings. In addition, the educational material for patients and healthcare professionals will be revised accordingly. Patients who have questions about their treatment or their risk of serious side effects should contact their doctor. More information is available in EMA’s public health communication . EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines The PRAC has confirmed its recommendation to withdraw the marketing authorisations for amfepramone obesity medicines. This follows a re-examination of its previous recommendation of June 2022, which was requested by the companies that market these medicines. The recommendation follows a review which found that measures to restrict the use of these medicines for safety reasons have not been sufficiently effective. It found that the medicines were being used for longer than the recommended maximum period of 3 months, thereby potentially increasing the risk of serious side effects, such as pulmonary arterial hypertension (high blood pressure in the lungs) and dependency. The medicines were also being used in patients with a history of heart disease or psychiatric disorders, increasing their risk of heart and psychiatric problems. In addition, there was evidence of use during pregnancy, which could pose risks to the unborn baby. The review considered all available information relating to these concerns, including data from two studies on the use of amfepramone medicines in Germany and in Denmark. In addition, the PRAC received advice from a group of experts, comprising endocrinologists, cardiologists and a patient representative. The PRAC considered introducing further measures to minimise the risk of side effects but could not identify any that would be sufficiently effective. The PRAC therefore concluded that the benefits of amfepramone medicines do not outweigh their risks and recommended that the medicines be removed from the market in the EU. The PRAC recommendation will now be sent to the CMDh 2 for its consideration. More information is available in EMA’s public health communication . Comirnaty and Spikevax: heavy menstrual bleeding added as a side effect The PRAC has recommended that heavy menstrual bleeding should be added to the product information as a side effect of unknown frequency of the mRNA COVID-19 vaccines Comirnaty and Spikevax. Heavy menstrual bleeding (heavy periods) may be defined as bleeding characterised by an increased volume and/or duration which interferes with the person’s physical, social, emotional and material quality of life. Cases of heavy menstrual bleeding have been reported after the first, second and booster doses of Comirnaty and Spikevax. The PRAC finalised the assessment of this safety signal after reviewing the available data, including cases reported during clinical trials , cases spontaneously reported in Eudravigilance and findings from the medical literature. After reviewing the data, the Committee concluded that there is at least a reasonable possibility that the occurrence of heavy menstrual bleeding is causally associated with these vaccines and therefore recommended the update of the product information . The available data reviewed involved mostly cases which appeared to be non-serious and temporary in nature. Menstrual disorders in general are quite common and they can occur for a wide range of reasons. This includes some underlying medical conditions. Any person who experiences postmenopausal bleeding or is concerned about a change in menstruation should consult their doctor. There is no evidence to suggest the menstrual disorders experienced by some people have any impact on reproduction and fertility. Available data provides reassurance about the use of mRNA COVID-19 vaccines before and during pregnancy. A review carried out by EMA’s Emergency Task Force showed that mRNA COVID-19 vaccines do not cause pregnancy complications for expectant mothers and their babies, and they are as effective at reducing the risk of hospitalisation and deaths in pregnant people as they are in non-pregnant people. The Committee reiterates that the totality of data available confirms that the benefits of these vaccines greatly outweigh the risks. Healthcare professionals and patients are encouraged to continue to report cases of heavy menstrual bleeding to their national authorities. The PRAC will continue to monitor for cases of this condition and will communicate further if new recommendations are warranted. Ustekinumab (Stelara): warning on use of live vaccines in infants whose mothers received ustekinumab during pregnancy The PRAC has recommended adding a warning to the product information for ustekinumab (Stelara) on the use of live vaccines in infants whose mothers received ustekinumab during their pregnancy. Ustekinumab is authorised in the European Union to treat severe plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The product information already advises that it is preferable to avoid use of ustekinumab during pregnancy. People of childbearing potential are advised to avoid becoming pregnant and must use adequate contraception while using Stelara and for at least 15 weeks after the last Stelara treatment. The Committee has reviewed the available evidence regarding use of ustekinumab during pregnancy, including observational studies from the EU, United States and Canada, as well as a cumulative review requested from the marketing authorisation holder . Ustekinumab can cross the placenta. It has been detected in the serum (the fluid component of the blood) of infants who were exposed to ustekinumab in utero (infants whose mothers were treated with the medicine during pregnancy). Although the data on ustekinumab are limited, the risk of infection may be increased after birth in infants who were exposed to ustekinumab in utero. Therefore, the PRAC recommended that, in infants who were exposed to ustekinumab in utero, the administration of live vaccines (vaccines made from a virus or bacterium that has been weakened) is not recommended for six months following birth or until the infant’s serum levels of ustekinumab are undetectable. In case of a clear clinical benefit for the individual infant, administration of a live vaccine might be considered earlier, if the infant’s serum levels of ustekinumab are undetectable. The PRAC ’s recommendation will be forwarded to EMA’s human medicines committee ( CHMP ) for adoption. New safety information for healthcare professionals As part of its advice on safety-related aspects to other EMA committees, the PRAC discussed direct healthcare professional communications (DHPCs) containing important information for Janus kinase (JAK) inhibitors and amfepramone medicines. Janus kinase (JAK) inhibitors: measures to minimise risk of serious side effects This DHPC will inform healthcare professionals about the risk minimisation measures for certain serious side effects associated with Janus kinase (JAK) inhibitors used in chronic inflammatory disorders. Amfepramone medicines: advice to patients about other treatment options This DHPC will inform healthcare professionals on the conclusion of the re-examination of EMA’s recommendation on amfepramone-containing medicines and on the need to advise patients about other treatment options. The DHPC for amfepramone medicines will be forwarded to the Coordination Group for Mutual Recognition and Decentralised Procedures – Human ( CMDh ) and the DHPC for Janus kinase inhibitors will be forwarded to EMA’s human medicines committee ( CHMP ). Following the CHMDh and CHMP opinion, the DHPCs will be disseminated to healthcare professionals by the marketing authorisation holder , according to an agreed communication plan, and published on the ‘ Direct healthcare professional communications ’ page and in national registers in EU Member States. 1 Ytterberg SR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. New Engl J Med 2022; 3 86(4):316-326. doi: 10.1056/NEJMoa2109927 2 Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human Agenda List item Agenda of the PRAC meeting 24-27 October 2022 (PDF/431.23 KB) (new) Draft First published: 24/10/2022 EMA/785930/2022 PRAC statistics: November 2022 List item PRAC statistics: November 2022 (PDF/542.81 KB) (new) First published: 28/10/2022 Glossary: Safety signal assessments . A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine and an adverse event that warrants further investigation. Safety signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. More information can be found under ' Signal management '. Periodic safety update reports , abbreviated as PSURs, are reports prepared by the marketing authorisation holder to describe the worldwide safety experience with a medicine in a defined period after its authorisation. PSURs for medicinal products that contain the same active substance or the same combination of active substances but have different marketing authorisations and are authorised in different EU Member States, are jointly assessed in a single assessment procedure. More information can be found under ' Periodic safety update reports: questions and answers '. Risk management plans , abbreviated as RMPs, are detailed descriptions of the activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicines. Companies are required to submit an RMP to EMA when applying for a marketing authorisation . RMPs are continually updated throughout the lifetime of the medicine as new information becomes available. More information is available under 'Risk-management plans '. Post-authorisation safety studies , abbreviated as PASSs, are studies carried out after a medicine has been authorised to obtain further information on its safety, or to measure the effectiveness of risk-management measures. The PRAC assesses the protocols (aspects related to the organisation of a study) and the results of PASSs. More information can be found under ' Post-authorisation safety studies '. Referrals are procedures used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral related to safety of medicines, the PRAC is requested by a Member State or the European Commission to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. More information can be found under referral procedures . Summary safety reports have been introduced as part of the enhanced safety monitoring of COVID-19 vaccines. Marketing authorisation holders are required to submit these reports to EMA, starting on a monthly basis. Their submission complements the submission of PSURs. For more information see EMA’s pharmacovigilance plan for COVID-19 vaccines .